Literature DB >> 16469271

Challenges for gene therapy for muscular dystrophy.

Jerry R Mendell1, K Reed Clark.   

Abstract

Gene therapy for muscular dystrophy represents a promising avenue of pursuit for a disease with a limited repertoire of treatment. Recent successes in the research arena using adeno-associated viral vectors should accelerate the movement of gene-based therapeutics for muscle disorders into the clinic. Nevertheless, significant challenges remain before gene therapy can deliver on the promises avowed by early pioneers of the field. This review examines recent progress and the hurdles remaining to achieve gene-based treatment therapies for muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469271     DOI: 10.1007/s11910-996-0009-8

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  54 in total

1.  A tumultuous year for gene therapy.

Authors:  I M Verma
Journal:  Mol Ther       Date:  2000-11       Impact factor: 11.454

Review 2.  Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function.

Authors:  Daniel E Michele; Kevin P Campbell
Journal:  J Biol Chem       Date:  2003-01-29       Impact factor: 5.157

3.  Gene therapy put on hold as third child develops cancer.

Authors:  Erika Check
Journal:  Nature       Date:  2005-02-10       Impact factor: 49.962

4.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle.

Authors:  K R Clark; T J Sferra; P R Johnson
Journal:  Hum Gene Ther       Date:  1997-04-10       Impact factor: 5.695

6.  Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors.

Authors:  Anne-Kathrin Zaiss; Qiang Liu; Gloria P Bowen; Norman C W Wong; Jeffrey S Bartlett; Daniel A Muruve
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

7.  Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies.

Authors:  L Cordier; G P Gao; A A Hack; E M McNally; J M Wilson; N Chirmule; H L Sweeney
Journal:  Hum Gene Ther       Date:  2001-01-20       Impact factor: 5.695

8.  Mutation rates in the dystrophin gene: a hotspot of mutation at a CpG dinucleotide.

Authors:  Carolyn H Buzin; Jinong Feng; Jin Yan; William Scaringe; Qiang Liu; Johan den Dunnen; Jerry R Mendell; Steve S Sommer
Journal:  Hum Mutat       Date:  2005-02       Impact factor: 4.878

9.  Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals.

Authors:  M Koenig; E P Hoffman; C J Bertelson; A P Monaco; C Feener; L M Kunkel
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

10.  Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice.

Authors:  S F Phelps; M A Hauser; N M Cole; J A Rafael; R T Hinkle; J A Faulkner; J S Chamberlain
Journal:  Hum Mol Genet       Date:  1995-08       Impact factor: 6.150

View more
  1 in total

Review 1.  Duchenne muscular dystrophy: current cell therapies.

Authors:  Dorota Sienkiewicz; Wojciech Kulak; Bożena Okurowska-Zawada; Grażyna Paszko-Patej; Katarzyna Kawnik
Journal:  Ther Adv Neurol Disord       Date:  2015-07       Impact factor: 6.570

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.